TNGX - Tango Therapeutics names new chief medical officer

Tango Therapeutics (NASDAQ:TNGX) has appointed Marc Rudoltz as the company’s new Chief Medical Officer. An alumnus of the Massachusetts Institute of Technology (MIT) and SUNY-Upstate Medical University, Rudoltz has over 20 years of experience in leading clinical-stage drug development. A former clinical consultant for Blueprint Medicines (NASDAQ:BPMC), he has previously served as chief medical officer for companies including Deciphera Pharmaceuticals (NASDAQ:DCPH), and Constellation Pharmaceuticals. “Marc‘s deep experience in oncology-clinical development, and particular focus on targeted therapy, will be of great benefit as Tango advances into the clinic in the first half of 2022 with TNG908, our MTA-cooperative PRMT5 inhibitor,” remarked CEO, Barbara Weber. The company has also named Doug Barry, a 20-year veteran in law, as its General Counsel. In September, Tango (TNGX) recorded a weekly loss of over 20% to be among the worst performers in healthcare.

For further details see:

Tango Therapeutics names new chief medical officer